United Kingdom

Catalyst biosciences Q3 loss per share $1.34

Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Catalyst Biosciences Inc :Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update.Q3 loss per share $1.34.Catalyst Biosciences Inc - ‍phase 1/2 trial of factor IX CB 2679D is advancing with interim results expected by year-end​.Catalyst Biosciences Inc - ‍phase 2 trial of factor Fviia Marzeptacog Alfa (activated) on track for initiation by year-end​.Catalyst Biosciences- ‍believes existing capital resources will be sufficient to meet its projected operating requirements for at least next 12 months​. 

Company Quote

-0.27 -3.18%
9:00pm BST